cisplatin – Medxy AI

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

By MedXY 10/01/2025

A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.

Clinical Updates Oncology

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

By MedXY 09/20/2025

The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.

Nephrology Oncology Specialties

Predicting Chronic Kidney Disease After Cisplatin Treatment: Insights from Population-Level Data

By MedXY 08/22/2025

Cisplatin chemotherapy is associated with predictable kidney function decline, with pre-treatment eGFR effectively forecasting chronic kidney disease risk post-treatment. Simple models outperform complex approaches, offering practical clinical decision tools.